140 related articles for article (PubMed ID: 23912258)
1. Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC).
Alvarez-Fernandez C; Perez-Arnillas Q; Ruiz-Echeverria L; Rodriguez-Rubi D; Sanchez-Lorenzo L; Li-Torres W; Izquierdo-Manuel M; Berros JP; Luque-Cabal M; Jimenez-Fonseca P; Villanueva-Palicio N; Esteban-Gonzalez E
Invest New Drugs; 2014 Apr; 32(2):377-81. PubMed ID: 23912258
[TBL] [Abstract][Full Text] [Related]
2. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
6. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
7. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
8. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
9. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
11. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(12):1352-8. PubMed ID: 21148615
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
13. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.
Liu Y; Yin TJ; Zhou R; Zhou S; Fan L; Zhang RG
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1125-32. PubMed ID: 24067998
[TBL] [Abstract][Full Text] [Related]
14. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.
Ozasa H; Oguri T; Uemura T; Miyazaki M; Maeno K; Sato S; Ueda R
Cancer Sci; 2010 Jan; 101(1):161-6. PubMed ID: 19811498
[TBL] [Abstract][Full Text] [Related]
15. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed for the treatment of non-small cell lung cancer.
Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
[TBL] [Abstract][Full Text] [Related]
17. Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.
Christoph DC; Reyna-Asuncion B; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Gauler TC; Wohlschlaeger J; Schuler M; Eberhardt WE; Hirsch FR
Clin Lung Cancer; 2014 Sep; 15(5):320-30.e1-3. PubMed ID: 24993594
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.
Shaw AT; Varghese AM; Solomon BJ; Costa DB; Novello S; Mino-Kenudson M; Awad MM; Engelman JA; Riely GJ; Monica V; Yeap BY; Scagliotti GV
Ann Oncol; 2013 Jan; 24(1):59-66. PubMed ID: 22887466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]